With ongoing innovations in nanomedicine and drug delivery, BAY-876 or its derivatives may serve as promising agents for targeting SLC7A11-driven metabolic vulnerabilities in advanced PCa. Here, SLC7A11 is linked to posterior cortical atrophy.